Ubiquitin System: The Next Class of Drug Targets?
A Complex Role in Cellular Process & Growing Tool Set to Elucidate It
Bispecific Antibodies Close in on Cancer
Plotting Molecular Pincer Movements, Denying Cancer Room to Maneuver
Resolving Nonspecific Binding, Regeneration and Other Problems
Researchers Turn to Cloud Computing as Genomic Sequencing Data Threatens to Overwhelm Traditional IT Systems
Greg Lucier: Life after Life Tech
In a single decade, Greg Lucier, 49, transformed the relatively small firm Invitrogen into the international behemoth Life Technologies. Now that Thermo Fisher Scientific has completed its acquisition of Life Tech, Lucier says he may try “to serve in some appointed or possibly even elected capacity.” (For more on Greg Lucier, click here.) Would you vote for Lucier?